MediWound (NASDAQ:MDWD) Cut to Strong Sell at Zacks Research

Zacks Research cut shares of MediWound (NASDAQ:MDWD) from a hold rating to a strong sell rating in a report published on Monday,Zacks.com reports.

MDWD has been the topic of a number of other research reports. Weiss Ratings reissued a “sell (d-)” rating on shares of MediWound in a research note on Wednesday, October 8th. Wall Street Zen downgraded MediWound from a “hold” rating to a “sell” rating in a report on Friday, July 18th. Four research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. According to data from MarketBeat, MediWound presently has a consensus rating of “Hold” and an average target price of $32.25.

MediWound Price Performance

NASDAQ MDWD opened at $19.58 on Monday. MediWound has a 1-year low of $14.14 and a 1-year high of $22.50. The firm has a market capitalization of $217.14 million, a P/E ratio of -7.42 and a beta of 0.27. The business’s 50-day simple moving average is $17.62 and its 200-day simple moving average is $18.52.

MediWound (NASDAQ:MDWD) last posted its earnings results on Thursday, August 14th. The biopharmaceutical company reported ($1.23) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.55) by ($0.68). The business had revenue of $5.71 million for the quarter, compared to analyst estimates of $5.68 million. MediWound had a negative return on equity of 96.71% and a negative net margin of 142.18%. On average, equities research analysts expect that MediWound will post -2.66 EPS for the current fiscal year.

Institutional Trading of MediWound

A number of institutional investors and hedge funds have recently modified their holdings of the business. Silverberg Bernstein Capital Management LLC lifted its position in shares of MediWound by 41.9% in the 2nd quarter. Silverberg Bernstein Capital Management LLC now owns 147,535 shares of the biopharmaceutical company’s stock worth $2,858,000 after buying an additional 43,591 shares during the last quarter. Sheets Smith Investment Management acquired a new stake in MediWound during the third quarter worth about $362,000. Menora Mivtachim Holdings LTD. bought a new position in MediWound in the second quarter worth about $339,000. Marshall Wace LLP acquired a new position in MediWound in the second quarter valued at approximately $317,000. Finally, Jane Street Group LLC bought a new position in shares of MediWound during the second quarter valued at approximately $295,000. 46.83% of the stock is owned by institutional investors and hedge funds.

About MediWound

MediWound Ltd., a biopharmaceutical company, develops, manufactures, and commercializes novel, bio-therapeutic, and non-surgical solutions for tissue repair and regeneration in United States, Europe, and internationally. It markets NexoBrid, a biopharmaceutical product for the removal of eschar, a dead or damaged tissue in adults with deep partial- and full-thickness thermal burns to burn centers and hospitals burn units.